Systemic administration of GV1001 significantly inhibited the development of Pg-induced periodontal disease and demonstrated the ability to inhibit vascular inflammation, most likely by preventing the accumulation of Pg DNA, lipopolysaccharides (LPSs), and gingipains in the arterial wall. Here, JUP is linked to periodontal disorder.